

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US06/09078

A. CLASSIFICATION OF SUBJECT MATTER IPC(8): A61K 31/435(2006.01) USPC: 514/277 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/277 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) PubMed, US Patents		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2005/0043233 A1 (Stefanic et al.) 24 February 2005 (24.02.2005), entire document.	1-20
Y	Baselga et al. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Five Selected Solid Tumor Types. Journal of Clinical Oncology, 2002, Vol. 20, No. 21, pages 4292-4302.	1-20
Y	Monneret, C. Histone Deacetylase Inhibitors. European Journal of Medicinal Chemistry, 2005, Vol. 40, pages 1-13.	1-20
A	Deeb et al. Altered E-Cadherin and Epidermal Growth Factor Receptor Expressions are Associated with Patient Survival in Lung Cancer: A Study Utilizing High-Density Tissue Microarray and Immunohistochemistry. Modern Pathology, 2004, Vol. 17, pages 430-439.	21-35
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed	
Date of the actual completion of the international search 11 January 2007 (11.01.2007)		Date of mailing of the international search report 22 FEB 2007
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201		Authorized officer James D. Anderson Telephone No. 571-272-9038

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US06/09078

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Fuino et al. Histone Deacetylase Inhibitor LAQ824 Down-Regulates Her-2 and Sensitizes Human Breast Cancer Cells to Trastuzumab, Taxotere, Gemcitabine, and Etoposide B. Molecular Cancer Therapeutics, 2003, Vol. 2, pages 971-984.	1-35
T	WO 2006/082428 A2 (Lichenstein et al.) 10 August 2006 (10.08.2006), entire document.	1-35